Revita Could ‘Break The Pattern Of Chronic Medication’ For Obesity And T2D – Fractyl

Based on clinical evidence to date, including newly released findings in 11 patients at one year post-procedure, Fractyl Health believes that by resurfacing and reversing the pathology of the duodenal lining, its Revita system has the potential to become the first disease-modifying therapy that targets a root cause of obesity and type 2 diabetes.